Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.19
ALKS's Cash to Debt is ranked lower than
69% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. ALKS: 2.19 )
Ranked among companies with meaningful Cash to Debt only.
ALKS' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 1.59 Max: No Debt
Current: 2.19
Equity to Asset 0.73
ALKS's Equity to Asset is ranked higher than
57% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ALKS: 0.73 )
Ranked among companies with meaningful Equity to Asset only.
ALKS' s Equity to Asset Range Over the Past 10 Years
Min: -0.15  Med: 0.60 Max: 0.9
Current: 0.73
-0.15
0.9
F-Score: 4
Z-Score: 5.79
M-Score: -2.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -27.00
ALKS's Operating margin (%) is ranked higher than
59% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. ALKS: -27.00 )
Ranked among companies with meaningful Operating margin (%) only.
ALKS' s Operating margin (%) Range Over the Past 10 Years
Min: -96.39  Med: -7.62 Max: 41.29
Current: -27
-96.39
41.29
Net-margin (%) -19.87
ALKS's Net-margin (%) is ranked higher than
61% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. ALKS: -19.87 )
Ranked among companies with meaningful Net-margin (%) only.
ALKS' s Net-margin (%) Range Over the Past 10 Years
Min: -98.74  Med: -1.29 Max: 69.37
Current: -19.87
-98.74
69.37
ROE (%) -9.20
ALKS's ROE (%) is ranked higher than
68% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. ALKS: -9.20 )
Ranked among companies with meaningful ROE (%) only.
ALKS' s ROE (%) Range Over the Past 10 Years
Min: -187.82  Med: 0.11 Max: 65.64
Current: -9.2
-187.82
65.64
ROA (%) -6.71
ALKS's ROA (%) is ranked higher than
69% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ALKS: -6.71 )
Ranked among companies with meaningful ROA (%) only.
ALKS' s ROA (%) Range Over the Past 10 Years
Min: -24.69  Med: -0.42 Max: 27.26
Current: -6.71
-24.69
27.26
ROC (Joel Greenblatt) (%) -25.66
ALKS's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. ALKS: -25.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALKS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -70.03  Med: 6.41 Max: 131.93
Current: -25.66
-70.03
131.93
Revenue Growth (3Y)(%) 29.80
ALKS's Revenue Growth (3Y)(%) is ranked higher than
84% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ALKS: 29.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALKS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -22  Med: 11.30 Max: 69.1
Current: 29.8
-22
69.1
EPS Growth (3Y)(%) -24.20
ALKS's EPS Growth (3Y)(%) is ranked lower than
73% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ALKS: -24.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALKS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.2  Med: 16.60 Max: 226.4
Current: -24.2
-24.2
226.4
» ALKS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ALKS Guru Trades in Q1 2015

Jim Simons 198,686 sh (+210.51%)
Vanguard Health Care Fund 6,229,583 sh (+0.05%)
Ken Fisher 107,164 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 26,951 sh (-3.23%)
Pioneer Investments 252,166 sh (-10.44%)
» More
Q2 2015

ALKS Guru Trades in Q2 2015

Jim Simons 229,286 sh (+15.40%)
Pioneer Investments 287,959 sh (+14.19%)
Murray Stahl 25,000 sh (unchged)
Ken Fisher 107,164 sh (unchged)
Vanguard Health Care Fund 6,229,583 sh (unchged)
Jeff Auxier 26,851 sh (-0.37%)
» More
Q3 2015

ALKS Guru Trades in Q3 2015

George Soros 7,900 sh (New)
Ken Fisher 119,920 sh (+11.90%)
Vanguard Health Care Fund 6,879,583 sh (+10.43%)
Pioneer Investments 300,413 sh (+4.32%)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 26,851 sh (unchged)
Jim Simons Sold Out
» More
Q4 2015

ALKS Guru Trades in Q4 2015

Ken Fisher 120,327 sh (+0.34%)
Jeff Auxier 26,851 sh (unchged)
Vanguard Health Care Fund 6,851,996 sh (-0.40%)
» More
» Details

Insider Trades

Latest Guru Trades with ALKS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 108.70
ALKS's Forward P/E is ranked lower than
92% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 19.53 vs. ALKS: 108.70 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.22
ALKS's P/B is ranked lower than
54% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. ALKS: 3.22 )
Ranked among companies with meaningful P/B only.
ALKS' s P/B Range Over the Past 10 Years
Min: 1.66  Med: 4.25 Max: 379.8
Current: 3.22
1.66
379.8
P/S 6.82
ALKS's P/S is ranked higher than
58% of the 620 Companies
in the Global Biotechnology industry.

( Industry Median: 10.07 vs. ALKS: 6.82 )
Ranked among companies with meaningful P/S only.
ALKS' s P/S Range Over the Past 10 Years
Min: 2.19  Med: 7.09 Max: 18.8
Current: 6.82
2.19
18.8
Shiller P/E 657.47
ALKS's Shiller P/E is ranked lower than
98% of the 50 Companies
in the Global Biotechnology industry.

( Industry Median: 51.54 vs. ALKS: 657.47 )
Ranked among companies with meaningful Shiller P/E only.
ALKS' s Shiller P/E Range Over the Past 10 Years
Min: 418.54  Med: 547.92 Max: 1587.6
Current: 657.47
418.54
1587.6
Current Ratio 4.99
ALKS's Current Ratio is ranked higher than
53% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. ALKS: 4.99 )
Ranked among companies with meaningful Current Ratio only.
ALKS' s Current Ratio Range Over the Past 10 Years
Min: 2.01  Med: 6.24 Max: 15.4
Current: 4.99
2.01
15.4
Quick Ratio 4.81
ALKS's Quick Ratio is ranked higher than
54% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ALKS: 4.81 )
Ranked among companies with meaningful Quick Ratio only.
ALKS' s Quick Ratio Range Over the Past 10 Years
Min: 1.95  Med: 6.04 Max: 15.4
Current: 4.81
1.95
15.4
Days Inventory 109.84
ALKS's Days Inventory is ranked higher than
56% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. ALKS: 109.84 )
Ranked among companies with meaningful Days Inventory only.
ALKS' s Days Inventory Range Over the Past 10 Years
Min: 69.07  Med: 100.75 Max: 166.33
Current: 109.84
69.07
166.33
Days Sales Outstanding 80.36
ALKS's Days Sales Outstanding is ranked lower than
59% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. ALKS: 80.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALKS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.46  Med: 82.14 Max: 90.21
Current: 80.36
27.46
90.21
Days Payable 67.29
ALKS's Days Payable is ranked higher than
56% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. ALKS: 67.29 )
Ranked among companies with meaningful Days Payable only.
ALKS' s Days Payable Range Over the Past 10 Years
Min: 39.15  Med: 65.98 Max: 561.6
Current: 67.29
39.15
561.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.12
ALKS's Price/Net Cash is ranked lower than
82% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 5.23 vs. ALKS: 17.12 )
Ranked among companies with meaningful Price/Net Cash only.
ALKS' s Price/Net Cash Range Over the Past 10 Years
Min: 3.39  Med: 12.40 Max: 115.47
Current: 17.12
3.39
115.47
Price/Net Current Asset Value 9.06
ALKS's Price/Net Current Asset Value is ranked lower than
69% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 4.85 vs. ALKS: 9.06 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALKS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.39  Med: 11.01 Max: 343
Current: 9.06
2.39
343
Price/Tangible Book 5.01
ALKS's Price/Tangible Book is ranked lower than
61% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ALKS: 5.01 )
Ranked among companies with meaningful Price/Tangible Book only.
ALKS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.8  Med: 9.50 Max: 336
Current: 5.01
1.8
336
Price/Projected FCF 3.83
ALKS's Price/Projected FCF is ranked lower than
57% of the 150 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. ALKS: 3.83 )
Ranked among companies with meaningful Price/Projected FCF only.
ALKS' s Price/Projected FCF Range Over the Past 10 Years
Min: 2  Med: 3.73 Max: 22.72
Current: 3.83
2
22.72
Price/Median PS Value 0.96
ALKS's Price/Median PS Value is ranked lower than
59% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. ALKS: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
ALKS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.42  Med: 1.81 Max: 14.19
Current: 0.96
0.42
14.19
Earnings Yield (Greenblatt) (%) -2.42
ALKS's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. ALKS: -2.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALKS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.42  Med: 2.30 Max: 53.4
Current: -2.42
-2.42
53.4

More Statistics

Revenue(Mil) $640
EPS $ -0.85
Beta2.25
Short Percentage of Float5.30%
52-Week Range $28.73 - 80.71
Shares Outstanding(Mil)150.06

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 615 713 800
EPS($) -0.83 -0.35 0.30
EPS without NRI($) -0.83 -0.35 0.30

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:8AK.Germany,
Alkermes PLC is a biotechnology company. The Company is engaged in developing, manufacturing and commercializing medicines. The Company has a portfolio of commercial drug products and a clinical pipeline of product candidates that address central nervous system disorders such as addiction, schizophrenia and depression. The Company's products include CODAS, IPDAS, LinkeRx, MXDAS, NanoCrystal, SODAS, VERELAN and VIVITROL.
» More Articles for NAS:ALKS

Headlines

Articles On GuruFocus.com
AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs Jan 04 2016 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
Opportunistic Coat-tailing Jan 05 2010 
Weekly Guru Bargains Highlights: Coinstar Inc, Fair Isaac Corp, Alkermes Inc, American International Dec 12 2009 

More From Other Websites
Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences Feb 02 2016
Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences Feb 02 2016
Alkermes short bets built up ahead of depression drug setback Jan 28 2016
Alkermes Initiates Early-Stage Study on Alzheimer's Drug Jan 27 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Jan 25 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Jan 25 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Jan 25 2016
8 Things That Could Lift Biotech Stocks Out of Bear Market Jan 24 2016
4 Stocks That Punished Shareholders Last Week Jan 23 2016
Alkermes Hit 52-Week Low on Unfavorable Phase III Data Jan 22 2016
Alkermes Learns Makeovers Aren't Easy Jan 22 2016
[$$] Business Watch Jan 21 2016
Why These 5 Stocks Are Plummeting Today Jan 21 2016
[$$] Alkermes Depression Drug Disappoints Jan 21 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of... Jan 21 2016
Alkermes Hits Two-Year Low On Depression Drug Failure Jan 21 2016
Alkermes downgraded by Morgan Stanley and JP Morgan Jan 21 2016
Alkermes Falls Most Since 2002 as Depression Drug Trials Fail Jan 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK